Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Price, Quote, News and Overview

NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD

27.85  -0.37 (-1.31%)

After market: 27.85 0 (0%)

CGON Quote, Performance and Key Statistics

CG ONCOLOGY INC

NASDAQ:CGON (2/21/2025, 8:08:12 PM)

After market: 27.85 0 (0%)

27.85

-0.37 (-1.31%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High47.78
52 Week Low25.77
Market Cap2.08B
Shares74.84M
Float67.25M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO01-25 2024-01-25


CGON short term performance overview.The bars show the price performance of CGON in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

CGON long term performance overview.The bars show the price performance of CGON in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of CGON is 27.85 USD. In the past month the price decreased by -9.43%. In the past year, price decreased by -36.14%.

CG ONCOLOGY INC / CGON Daily stock chart

CGON Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.97 357.10B
AMGN AMGEN INC 15.29 162.72B
GILD GILEAD SCIENCES INC 23.85 137.00B
VRTX VERTEX PHARMACEUTICALS INC 1669.79 124.40B
REGN REGENERON PHARMACEUTICALS 15.34 76.56B
ARGX ARGENX SE - ADR N/A 39.16B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.32B
BNTX BIONTECH SE-ADR N/A 28.77B
ONC BEIGENE LTD-ADR N/A 27.25B
NTRA NATERA INC N/A 21.43B
BIIB BIOGEN INC 8.54 20.49B
SMMT SUMMIT THERAPEUTICS INC N/A 16.31B

About CGON

Company Profile

CGON logo image CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 61 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene is initially in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its lead candidate, BOND-003 is a targeted oncolytic intravesically delivered immunotherapy agent that is in Phase II for the treatment of Bacillus Calmette Guerin (BCG) unresponsive and intermediate risk NMIBC disease. Its other product candidate CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Company Info

CG ONCOLOGY INC

400 Spectrum Center Drive, Suite 2040

Irvine CALIFORNIA US

Employees: 61

Company Website: https://www.cgoncology.com/

Phone: 19492886298

CG ONCOLOGY INC / CGON FAQ

What is the stock price of CG ONCOLOGY INC today?

The current stock price of CGON is 27.85 USD. The price decreased by -1.31% in the last trading session.


What is the ticker symbol for CG ONCOLOGY INC stock?

The exchange symbol of CG ONCOLOGY INC is CGON and it is listed on the Nasdaq exchange.


On which exchange is CGON stock listed?

CGON stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CG ONCOLOGY INC stock?

14 analysts have analysed CGON and the average price target is 69.8 USD. This implies a price increase of 150.62% is expected in the next year compared to the current price of 27.85. Check the CG ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CG ONCOLOGY INC worth?

CG ONCOLOGY INC (CGON) has a market capitalization of 2.08B USD. This makes CGON a Mid Cap stock.


How many employees does CG ONCOLOGY INC have?

CG ONCOLOGY INC (CGON) currently has 61 employees.


What are the support and resistance levels for CG ONCOLOGY INC (CGON) stock?

CG ONCOLOGY INC (CGON) has a support level at 27.84 and a resistance level at 28.07. Check the full technical report for a detailed analysis of CGON support and resistance levels.


Is CG ONCOLOGY INC (CGON) expected to grow?

The Revenue of CG ONCOLOGY INC (CGON) is expected to grow by 412.82% in the next year. Check the estimates tab for more information on the CGON EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CG ONCOLOGY INC (CGON) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CG ONCOLOGY INC (CGON) stock pay dividends?

CGON does not pay a dividend.


What is the Price/Earnings (PE) ratio of CG ONCOLOGY INC (CGON)?

CG ONCOLOGY INC (CGON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.31).


What is the Short Interest ratio of CG ONCOLOGY INC (CGON) stock?

The outstanding short interest for CG ONCOLOGY INC (CGON) is 10.09% of its float. Check the ownership tab for more information on the CGON short interest.


CGON Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

CGON Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CGON. CGON has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CGON Financial Highlights

Over the last trailing twelve months CGON reported a non-GAAP Earnings per Share(EPS) of -5.31. The EPS decreased by -54.78% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -14.17%
ROE -14.59%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%57.83%
Sales Q2Q%-78.82%
EPS 1Y (TTM)-54.78%
Revenue 1Y (TTM)6.81%

CGON Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to CGON. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of 1.8% and a revenue growth 412.82% for CGON


Ownership
Inst Owners95.99%
Ins Owners1.54%
Short Float %10.09%
Short Ratio9.06
Analysts
Analysts82.86
Price Target69.8 (150.63%)
EPS Next Y1.8%
Revenue Next Year412.82%